CTi Biopharma — Cell Therapeutics — Merger or Acquisition (June 2003)
62 slides from CTi Biopharma's merger presentation, Jun 26, 2003
Slide 1: Making cancer more treatable
[GRAPHIC] cti Making cancer more treatable CELL THERAPEUTICS, INC. NASDAQ: CTIC
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and beliefs and are subject to a number of facto
Slide 3: Where You Can Find Additional Information
Where You Can Find Additional Information Cell Therapeutics, Inc. (CTI) will file a proxy statement/prospectus and other documents concerning the proposed merger transaction with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read the proxy statement/prospe
Slide 4: Highlights
Highlights • XYOTAX in phase III trials - Fast track status in NSCLC - GOG ovarian cancer trial • TRISENOX 100% compounded annual growth rate - Profitable business unit in 2003 • Pixantrone best in class - Potential accelerated registration aggressive NHL • Strong financial position
Slide 5: Oncology Pipeline
Oncology Pipeline Preclinical Phase I Phase II Phase III NDA Marketed TRISENOX ® Approved for relapsed or refractory acute promyelocytic leukemia (APL) Multiple myeloma, myelodysplasia, myelogenous leukemia and other cancers XYOTAX ™ Non-small cell lung and ovarian cancers Pixantrone Non-Hodgkin’s l
Slide 6: XYOTAX
XYOTAX (polyglutamate paclitaxel) A safer, potentially more effective taxane
Slide 7: XYOTAX Accumulates in the Tumor
XYOTAX Accumulates in the Tumor [GRAPHIC]
Slide 8: XYOTAX Enters Cancer Cells
XYOTAX Enters Cancer Cells Through Different Mechanism than Taxol ® [GRAPHIC]
Slide 9: XYOTAX Tumor Selective Release of Chemotherapy
XYOTAX Tumor Selective Release of Chemotherapy [GRAPHIC]
Slide 10: XYOTAX Target product profile
XYOTAX Target product profile XYOTAX Paclitaxel Docetaxel Premedications No Yes Yes Infusion time 10 mins 3 hrs 1 hr Special infusion kits No Yes Yes Hair loss No Yes Yes Neuropathy Infrequent Frequent Infrequent Tolerability Excellent Fair Fair Efficacy Superior — — [GRAPHIC] cti
Slide 11: XYOTAX
XYOTAX • Designated fast track by FDA - “PS2 NSC lung cancer is incurable and current treatments offer modest benefit” - “XYOTAX has the potential to demonstrate improvement over available therapy in these patients based on anti-tumor activity reported in phase I and phase II clinical trials” • Robu
Slide 12: NSC Lung Cancer
NSC Lung Cancer Wcti
Slide 13: Phase II XYOTAX Front Line PS2 NSC Lung Cancer
Phase II XYOTAX Front Line PS2 NSC Lung Cancer • PS2 accounts for 20-30% of 136,000 patients with NSC lung cancer • Current treatments are poorly tolerated (median 2 doses) • Disease progresses rapidly - Median 6 weeks - Median survival poor (2.4 – 3.9 months)* • High unmet need — accelerated regula
Slide 14: XYOTAX Phase II High Risk NSC Lung Cancer
XYOTAX Phase II High Risk NSC Lung Cancer Patient Characteristics • XYOTAX 175 mg/m 2 every 3 weeks • n = 28 patients treated • Median age 76 (range 49-88) Performance status Disease stage PS0 6 (21%) IIIB 8 (29%) PS1 14 (50%) IV 20 (71%) PS2 8 (29%) *Data presented at ASCO 2003
Slide 15: XYOTAX Phase II High Risk: Number of Treatment Cycles
XYOTAX Phase II High Risk NSC Lung Cancer Number of Treatment Cycles Received 14 patients (64%) ³ 4 cycles of treatment 6 patients (27%) 6 cycles of treatment 2 patients (9%) 8 cycles of treatment *Data presented at ASCO 2003
Slide 16: XYOTAX Phase II High Risk: Adverse Events
XYOTAX Phase II High Risk NSC Lung Cancer Adverse Events (n = 28) Grade III Grade IV Neuropathy Neutropenia Febrile neutropenia Anemia Hair loss Hypersensitivity *Generalized weakness, fatigue and neuropathy were seen mostly in patients with concomitant progressive disease and significant disease re
Slide 17: Phase II XYOTAX Efficacy (PS2)
Phase II XYOTAX NSC Lung Cancer Efficacy (PS2) Objective Response Rate Median # of Doses Time to Progression (months) Survival (months) XYOTAX (175 mg/m2)* ~10% 2.6 ³ 5.4 Efficacy (PS2) Paclitaxel (225 mg/m2)** ~10% 1.5 2.4 * ASCO 2003 poster ** ASCO 2002 presentation, R.C. Lilenbaum
Slide 18: XYOTAX Phase III NSC Lung Cancer Studies
XYOTAX Phase III NSC Lung Cancer Studies Trial Design Comparator dose (mg/m2) XYOTAX dose (mg/m2) Primary Endpoint # of pts Data Release STELLAR 2 2nd Line NSC Lung Superiority Open-label Randomized Docetaxel 75 Q3 weeks Q3 wks Survival 2H04 STELLAR 3 1st Line NSC Lung PS2 Superiority Open-label Ran
Slide 19: Ovarian Cancer
Ovarian Cancer Wcti
Slide 20: XYOTAX Phase II Ovarian Patient Characteristics
XYOTAX Phase II Ovarian Patient Characteristics (n=99) Age Median (range) 57 (29-89) Number Prior Regimens 39 pts* 3 or 4 29 pts 5 or 6 18 pts 7-12 13 pts *1 patient had 1 prior regimen
Slide 21: XYOTAX Phase II Ovarian Adverse Events
XYOTAX Phase II Ovarian Adverse Events (n=99) Grade III Grade IV Hematologic Hematologic 18 (18%) 4 (4%) Neutropenia 15 (15%) 8 (8%) Anemia 6 (6%) Thrombocytopenia 1 (1%) Non-hematologic Hepatic Renal Gastrointestinal 2 (2%) Infection Musculoskeletal 1 (1%) Constitutional (fatigue) 5 (5%) Neuropathy
Slide 22: XYOTAX Phase II Ovarian Tumor Response
XYOTAX Phase II Ovarian Tumor Response Platinum Sensitive # Prior Regimens Platinum Resistant # Prior Regimens (n=18*) ³ 3 (n=24) 1 or 2 (n=21) ³ 3 (n=36) PR 8 (33%) 1 (4%) 3 (14%) 3 (8%) SD 2 (11%) 11 (46%) 3 (14%) 11 (31%) Presented at the ONS Meeting 2003 *1 patient had 1 prior regimen /
Slide 23: XYOTAX Phase III Ovarian Cancer
XYOTAX Phase III Ovarian Cancer Gynecologic Oncology Group Trial Trial Design Comparator dose (mg/m2) XYOTAX dose (mg/m2) Primary Endpoint # of pts Data Release 1st Line Ovarian Non-Inferiority Open-label Randomized Paclitaxel 175 + carbo AUC 6 Q3 weeks Paclitaxel 175 Q4 weeks x 12 for CRs 210 + Car
Slide 24: XYOTAX Estimated US Regulatory Timelines
XYOTAX Estimated US Regulatory Timelines 1H 04 2H 04 1H 05 2H 05 1H 06 2H 06 First line NSC Lung (STELLAR 3) NDA Submission Approval First line NSC Lung (STELLAR 4) NDA Submission Approval Second line NSC Lung (STELLAR 2) NDA Submission Approval First line Ovarian NDA Submission Approval
Slide 25: TRISENOX
TRISENOX (arsenic trioxide) injection Indicated for the induction of remission and consolidation for patients with relapsed or refractory acute promyelocytic leukemia (APL)
Slide 26: TRISENOX Commercial Opportunity
TRISENOX Commercial Opportunity • Product marketed in US, and EU • 100% CAGR forecasted in 2003 • $150+ million peak U.S. sales potential • >40 market expansion clinical trials ongoing • Gaining share in U.S. blood related cancer market - EU penetration limited to initial label (APL) • Potential lab
Slide 27: TRISENOX US Patient Mix
TRISENOX US Patient Mix 1Q02 1Q03 APL 15% 10% Myeloma 43% 43% MDS 29% 41% Other 13% 6%
Slide 28: TRISENOX Profitable Commercial Effort in 2003
TRISENOX Profitable Commercial Effort in 2003 Sales $ Millions 2001 $6.0M 2002 $ 11.7M 2003 (E) $ 24.0M 2004 (E) $ 43.0M Source for 2004 estimate: CIBC World Markets
Slide 29: TRISENOX Impressive efficacy data in MDS
TRISENOX ® Impressive efficacy data in MDS MDS (145 patients, 81 evaluable) • 32% objective responses in both low and high risk • Decreases or eliminates RBC and platelet transfusion dependence - 80% of responding pts became transfusion independent lasting up to 2 yrs • Well tolerated, no dose reduc
Slide 30: TRISENOX Impressive efficacy data in multiple myeloma
TRISENOX Impressive efficacy data in multiple myeloma Multiple myeloma (86 patients, 78 evaluable) • High response rates in combination with dexamethasone, vitamin C, and melphalan - ~ 40% objective responses ( ³ PR) - Marked improvement in kidney function • Well tolerated; manageable side effects •
Slide 31: Commercial Synergies
Commercial Synergies Key Products Hematology Solid Tumors TRISENOX ® APL, CML, MDS, Multiple myeloma Pixantrone Aggressive NHL Indolent NHL Breast cancer Prostate cancer XYOTAX ™ NSC lung cancer Ovarian cancer CT-2106 Colorectal cancer Small cell lung cancer
Slide 32: Commercial Operations: Drivers for Expansion
Commercial Operations Drivers for Expansion [GRAPH] 2003 2004 2005 2006 TRISENOX APL label, > 40 clinical trials TRISENOX MDS label TRISENOX Myeloma label XYOTAX Phase III trials XYOTAX NDA XYOTAX NSCLC label Pixantrone Phase III trials Pixantrone Phase III trials Pixantrone NDA Pixantrone Aggressiv
Slide 33: Pixantrone
Pixantrone [GRAPHIC]
Slide 34: Pixantrone (from Novuspharma merger)
Pixantrone (from Novuspharma merger) • New potential best-in-class DNA intercalator with improved efficacy and safety • Phase III in aggressive NHL targeted Q1 –’04 • Should qualify for accelerated regulatory review • Potential NDA in 2005 • Initial indication could generate $150+ million annual sal
Slide 35: DNA Intercalators
DNA Intercalators • Established efficacy - Cornerstone of chemotherapy for breast cancer, leukemias, and lymphomas - Standard treatment in blood-born tumors – curative - Breast cancer – highly effective as adjuvant and frontline therapy - Only therapy for advanced forms of multiple sclerosis • Howev
Slide 36: DNA Intercalators with improved efficacy and safety
DNA Intercalators With improved efficacy and safety • Novuspharma’s approach - Alter chemical groups responsible for free-radical production and cardiac toxicity [GRAPHIC] • Target markets - Unmet clinical need in second-line therapy (NHL) - Replace current DNA intercalators as safer treatment in fi
Slide 37: Pixantrone
Pixantrone Doxorubicin Mitoxantrone Pixantrone Efficacy in hematology +++ ++ ++++ Efficacy in solid tumors ++/+++ ++ ++ Safety (esp. cardiac) + ++ ++++ • Superior anti-tumor activity in P388 and L1210 murine leukemias vs. Dx and Mitox • Curative in YC-8 murine lymphoma • Wide therapeutic window—effe
Slide 38: Effect of pixantrone and mitoxantrone on survival in YC-8 lymphoma model
Effect of pixantrone and mitoxantrone (MITOX) on survival in the YC-8 lymphoma model (iv/iv + 1,5,9) [GRAPH]
Slide 39: Pixantrone Experimental cardiotoxicity
Pixantrone Experimental cardiotoxicity [GRAPHIC APPEARS HERE]
Slide 40: Pixantrone Target product profile
Pixantrone Target product profile • Superior safety - Cardiac toxicity profile superior to existing agents - Not toxic to tissues, eliminates need for central line - Less severe nausea and vomiting • Impressive efficacy - Long lasting complete remissions in heavily treated NHL patients - As single a
Slide 41: Pixantrone Clinical Summary
Pixantrone Clinical Summary • Extensive clinical trial experience - >170 patients - 7 phase I, II trials • Initial market entry into area of high unmet need - 3rd-line aggressive NHL - Currently no approved therapies - Market size ~15,000 patients • Potential label expansion - Relapsed indolent NHL
Slide 42: Pixantrone Single Agent Activity in Relapsed/Resistant Aggressive NHL
Pixantrone Impressive Single Agent Activity in Relapsed/Resistant Aggressive NHL Patient NHL Status Prior Rx mg/m 2 Resistant Prior Rx Response (Pix dose) Duration (mos) M-80 DLC 1 st Rel Dx380 Yes uPR(650) NA F-79 DLC 2 nd Rel Dx400 Yes CR(1530) F-65 DLC 2 nd Rel Dx400 Yes CR(1530) M-65 DLC 3 rd Re
Slide 43: Pixantrone Single Agent Activity in Relapsed/Resistant Aggressive NHL
Pixantrone Impressive Single Agent Activity in Relapsed/Resistant Aggressive NHL Patient NHL Status Prior Rx mg/m 2 Resistant Prior Rx Response (Pix dose) Duration (mos) F-72 DLC 4 th Rel Dx300 Yes PR(1020) F-41 Mcy 3 rd Rel Dx300 No CR(1241) F-60 DLC 3 rd Rel Dx400 Yes PR(1020) NA M-78 Mant 2 nd Re
Slide 44: Pixantrone Single Agent Activity in Relapsed/Resistant Aggressive NHL
Pixantrone Impressive Single Agent Activity in Relapsed/Resistant Aggressive NHL • High response rates in relapsed/resistant aggressive NHL - ORR= >30% (7CRs/5PRs + 5uPRs) - Durable responses: TTP >8 months for responders • Well tolerated - Grade 4 neutropenia 13/33 (40%) - Grade 4 anemia/thrombocyt
Slide 45: Pixantrone U.S. Registration Strategy
Pixantrone U.S. Registration Strategy • Pivotal trial in 3rd line aggressive NHL - Compelling phase II clinical data - High unmet need - qualifies for accelerated review - No approved agents - non-randomized single open label trial ~120 pts - Enrollment completion late 2004 - NDA target Q4 2005 - Po
Slide 46: Preliminary Market Study
Preliminary Market Study % of physicians who would prescribe Pixantrone by line of therapy First Line Second Line Third Line Aggressive 47% 100% 100% Indolent 27% 67% 67% - Almost half of the physicians would try Pixantrone in place of doxorubicin in first line therapy for aggressive patients – most
Slide 47: Pixantrone U.S. Market Potential
Pixantrone U.S. Market Potential NHL indication only • Aggressive NHL incidence(55%) 151,877 - Stage III/IV (80%) 121,502 - Chemotherapy (front line-CHOP) 72,901 - Salvage chemotherapy 54,169 • Indolent NHL incidence (45%) 124,263 - Stage III/IV 68,345 - Chemotherapy (+/-Rituxan) 44,735 - Salvage ch
Slide 48: Key Objectives Next 12-18 Months
Key Objectives Next 12-18 Months • Gynecologic Oncology Group to initiate phase III study of XYOTAX in ovarian cancer • Complete enrollment of pivotal trials in non-small cell lung cancer • Successful merger with Novuspharma to maximize cost synergies and efficiencies • Initiate pivotal trial of Pix
Slide 49: Novuspharma
Novuspharma [GRAPHIC] cti
Slide 50: Strategic Rationale
Strategic Rationale Immediate Realizable Synergies • Greater revenue growth potential - TRISENOX gaining hematology market share MARKETED - XYOTAX in pivotal trials for lung cancer LAUNCH 2005 - Pixantrone in pivotal trials for NHL LAUNCH 2006 - Targeting profitability in 2005 • Strong combined bala
Slide 51: Overview of Novuspharma S.p.A.
Overview of Novuspharma S.p.A. • Pixantrone potential “best in class” safer, more effective anthracycline in pivotal trials for NHL • Strong balance sheet: ~$120 million cash as of 3/31/03 • Former oncology drug development arm of Boehringer Mannheim, part of Hoffman La Roche - Expertise in pre-deve
Slide 52: Timing
Timing • Unanimous approval of both Boards • Subject to Novuspharma and CTI shareholder approval • Subject to approval of CTI’s application to list its shares on the Nuovo Mercato • Merger expected to close Q4 • Integration plan & team established - $18-20 million full year of cost savings expected
Slide 53: Specifics of Agreement
Specifics of Agreement • CTI to issue 16 million shares of CTIC to Novuspharma shareholders - Fixed exchange ratio 2.45 - Transaction value ~$235 million - Dual listing on NASDAQ and Nuovo Mercato • Novuspharma to have two seats on board with a third independent director to be nominated prior to clo
Slide 54: Company Profiles
Company Profiles CTI Novuspharma Therapeutic focus Cancer Cancer Key Products Marketed TRISENOX — Phase III XYOTAX Pixantrone Phase I/II CT-2106 (polyglutamate camptothecin) MT-201, BBR3576 Core competencies Sales & Marketing, Phase II/III, Target discovery & validation Preclinical (in vivo, PK/PD),
Slide 55: Operating Synergies: Center of excellence — Milan
Operating Synergies Center of excellence — Milan • Medicinal chemistry, lead optimization • Preclinical models, toxicology-ADME, analytical development, pharmacology • Clinical trials material production • PK/PD testing in Phase I • EU pharmacovigilance, QA/QC • European clinical development
Slide 56: Operating Synergies: Corporate Headquarters — Seattle
Operating Synergies Corporate Headquarters — Seattle • Target discovery/validation • Clinical Development - Phase I-III - Drug Regulatory Affairs - Drug Safety & Surveillance • Sales & Marketing
Slide 57: Making cancer more treatable
[GRAPHIC] cti Making cancer more treatable CELL THERAPEUTICS, INC. NASDAQ: CTIC The following sidebars are also being used by Dr. James Bianco of CTI at presentations involving the proposed business combination between CTI and Novuspharma.
Slide 58: Last Months in Review
Last 12 Months in Review Objective Status • Acquire late stage or commercial product • Novuspharma merger - Pixantrone in phase III - $18-$20m in annual operating synergies - $120M balance sheet • Reduce burn rate and secure adequate capital to grow commercial operations and see XYOTAX to NDA • $75M
Slide 59: Oncology Strategy
Oncology Strategy • Improve the safety and efficacy of existing agents which provide the cornerstone for standard of care - Taxanes (>$2B) XYOTAX ™ - Camptothecins (>$1B) CT-2106 - Anthracyclines (>$500M) Pixantrone • Develop new agents with unique mechanisms of tumor cell killing without more side
Slide 60: Hematology Commercial opportunity
Hematology Commercial opportunity 2002 Incidence 2002 Prevalence Total Hematologic 94,850 423,564 TRISENOX ® APL 1,050 2,535 Myelodysplastic Syndromes 15,200 35,562 Multiple Myeloma 14,600 49,542 Pixantrone AML 10,600 18,980 Indolent NHL 24,030 142,625 Aggressive NHL 29,370 174,320
Slide 61: Oncology Commercial opportunity
Oncology Commercial opportunity 2002 Incidence 2002 Prevalence Total Oncologic 516,144 3,132,334 XYOTAX ™ Advanced NSC lung 137,600 162,352 Ovarian 25,400 145,831 CT-2106 Small cell lung 34,380 57,983 Colorectal 147,500 930,083 Pixantrone Breast 212,600 1,836,085
Slide 62: Market Dynamics
Market Dynamics Hematology Oncology • Few “Big” pharma competitors • “Big” pharma dominates solid tumor space - Berlex, Genentech, Idec, Millenium, Celgene - Pfizer, Novartis, Glaxo, BMS, AstraZeneca, Lilly • Low S&M barriers to entry • Considerable sales and marketing barriers to entry • High incid
Cell Therapeutics — Merger or Acquisition (June 2003) on 6ix